Publication details
THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME.
| Authors | |
|---|---|
| Year of publication | 2010 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane. |
| Related projects: |